Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project
Open Access
- 7 July 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (9) , 1045-1052
Abstract
Cardiomyopathies are a group of inherited heart muscle disorders. Expressivity is variable and while sometimes mild, complications can result in sudden cardiac death (SCD) at any age, heart failure and stroke. In around a third of patients a monogenic cause is identifiable, and development of genetic therapies that aim to correct the underlying genetic defect is underway. Here we describe results of a survey designed to understand preliminary views of the patient community about genetic therapies in the context of disease burden. The internet survey was publicized with a bespoke information video via patient support groups in the UK and USA; 634 people responded of whom 96% had a personal and/or family history of cardiomyopathy. Findings show that concern about cardiomyopathy-related issues with a future dimension, such as disease progression, is significantly greater than concern about current issues. A total of 93.6% thought that genetic therapies should be developed for cardiomyopathy. A majority would consider participation in a genetic therapy trial in six scenarios varying by age and clinical situation significantly more in the scenario of an adult with symptomatic disease and evident progression than an asymptomatic adult with SCD risk, or a child. In all scenarios, a majority said that the chance genetic therapy would stop or slow progression, and risk of serious adverse and unintended effects, were important considerations. Qualitative analysis of free-text responses found that concern was often informed by family experience. Patient consideration of genetic therapy is likely to require individualized assessment of the benefits and risks.Keywords
Funding Information
- British Heart Foundation (BBC/19/3/35106, BBC/F/21/220106, BBC/19/3/35106, BBC/19/3/35106, BBC/19/3/35106, BBC/19/3/35106, BBC/19/3/35106, BBC/19/3/35106)
- NIHR Oxford Biomedical Research Centre
This publication has 35 references indexed in Scilit:
- Applications of Gene Therapy in CardiomyopathiesJACC: Heart Failure, 2023
- European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseasesJournal of Arrhythmia, 2022
- Translation of New and Emerging Therapies for Genetic CardiomyopathiesJACC: Basic To Translational Science, 2021
- Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic CardiomyopathyJournal of Genetic Counseling, 2018
- Quality of life metrics in arrhythmogenic right ventricular cardiomyopathy patients: The impact of age, shock and sexInternational Journal of Cardiology, 2017
- Posttraumatic Stress and Prolonged Grief After the Sudden Cardiac Death of a Young RelativeJAMA Internal Medicine, 2016
- New Perspectives on the Prevalence of Hypertrophic CardiomyopathyJACC, 2015
- Experiences, considerations and emotions relating to cardiogenetic evaluation in relatives of young sudden cardiac death victimsEuropean Journal of Human Genetics, 2013
- Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implicationsEuropean Journal of Human Genetics, 2013
- Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failureJACC, 2000